The Conversation (0)
- AustraliaNorth AmericaWorld
Investing News NetworkYour trusted source for investing success
Top Stocks
Top Resource Stocks
Top Tech Stocks
Top Life Science Stocks
Trending
Trending Articles
Trending Press Releases
Trending Companies
Trending Reports
Resource
Popular Lists
Investing Ideas
Outlook Reports
- Lithium Outlook
- Oil and Gas Outlook
- Gold Outlook Report
- Uranium Outlook
- Rare Earths Outlook
- All Outlook Reports
Investing Guides
Tech
Popular Lists
- Top Generative AI Stocks
- Top EV Stocks
- Biggest AI Companies
- Biggest Blockchain Stocks
- Biggest Cryptocurrency-mining Stocks
- Biggest Cybersecurity Companies
- Biggest Robotics Companies
- Biggest Social Media Companies
- Biggest Technology ETFs
- Artificial Intellgience ETFs
- Robotics ETFs
- Canadian Cryptocurrency ETFs
Investing Ideas
Outlook Reports
- Artificial Intelligence Outlook
- EV Outlook
- Cleantech Outlook
- Crypto Outlook
- Tech Outlook
- All Market Outlook Reports
Investing Guides
Life Science
Popular Lists
- Cannabis Weekly Round-Up
- Top Alzheimer's Treatment Stocks
- Top Biotech Stocks
- Top Plant-based Food Stocks
- Biggest Cannabis Stocks
- Biggest Pharma Stocks
- Longevity Stocks to Watch
- Psychedelics Stocks to Watch
- Top Cobalt Stocks
- Small Biotech ETFs to Watch
- Top Life Science ETFs
- Biggest Pharmaceutical ETFs
Outlook Reports
- Life Science Outlook
- Biotech Outlook
- Cannabis Outlook
- Pharma Outlook
- Psychedelics Outlook
- All Market Outlook Reports
Investing Guides
Cresco Labs issued its financial results for the third quarter and nine month period ended on September 30.
Cresco Labs (CSE:CL) issued its financial results for the third quarter and nine month period ended on September 30.
As quoted in the press release:
Financial Results for the Third Quarter Ended September 30, 2018
Revenue for the third quarter of 2018 was [US]$12.2 million, an increase of 335 [percent] compared to revenue of [US]$2.8 million for the third quarter of 2017. The increase in revenue was driven by market expansion and gains in market share in the states where the Company operates. Third quarter revenue increased 51 [percent] compared to [US]$8.1 million for the second quarter of 2018.
On a pro forma basis, revenue for the third quarter was [US]$16.3 million compared to [US]$11.8 million for the second quarter of 2018, an increase of 39 [percent].
Third quarter gross profit, before the gain from biological assets, was [US]$5.4 million, or 45 [percent] of revenues, compared to less than [US]$0.1 million, or 1 [percent] of revenues, for the third quarter of 2017 and [US]$3.5 million, or 43 [percent] of revenues, for the second quarter of 2018.
Net income for the third quarter was $3.9 million, compared to net loss of [US]$0.2 million for the prior-year period. Net income nearly doubled from [US]$2.0 million for the second quarter of 2018.
Click here to read the full press release.
Source: www.businesswire.com
Investing News Network websites or approved third-party tools use cookies. Please refer to the cookie policy for collected data, privacy and GDPR compliance. By continuing to browse the site, you agree to our use of cookies.